Drugs For Rare Diseases Have Become Uncommonly Rich Monopolies

Drugmakers have brought almost 450 orphan drugs to market and collected rich incentives by doing so. But nearly a third of the medicines aren’t new or were repurposed many times for financial gain. By Sarah Jane Tribble, Sydney Lupkin.
Read more: http://www.npr.org/sections/health-shots/2017/01/17/509506836/drugs-for-rare-diseases-have-become-uncommonly-rich-monopolies?source=Snapzu